Dr Reddy's Labs (500124) Jul 2026 Filing Analysis

Management stated that North America base-business growth was double digit in Q1FY27 and reaffirmed double-digit growth for the full year, excluding lenalidomide and semaglutide. (1 met, 1 revised across 2 tracked commitments)

The document confirms continued North America launch activity but does not report the number of ANDA filings or confirm achievement of the earlier six-filing H1 target. Six new products were launched in North America during Q3. (3 in progress across 3 tracked commitments)

Management is maintaining a pipeline of pending US regulatory applications, including Para IV and FTF opportunities. — target: 76 pending ANDAs and 3 pending NDAs, including 46 Para IVs and 24 FTFs

Launch abatacept upon approval, with the US approval goal date in mid-December 2026. — target: US launch upon approval; mid-December 2026 goal date (+1 more commitment)

The scale moat expanded through a broad launch and filing program: seven North American launches, eight European launches, 24 Emerging Market launches and 43 global generic filings in Q2 FY26. The later baseline shows an even broader footprint, including 48 Emerging Market countries, 21 European countries, six North American launches, 43 Emerging Market launches and 24 European launches. This indicates continued geographic reach and product-launch scale. (4 expanding)

Emerging Markets expanded, with revenue increasing 14% year over year and 18% sequentially to ₹1,655 Cr. Russia remained the largest contributor at 53% of the region, while the company launched 24 products and filed 32 new products in the quarter. The later baseline confirms stronger momentum, with the region reaching 23% of total revenue and 31% year-over-year growth. (5 expanding)

Global Generics remained the dominant business, accounting for 89% of revenue in Q2 FY26. Revenue grew 10% year over year to ₹7,850 Cr and 4% sequentially. This is an expanding revenue engine, although the later baseline shows that reported revenue subsequently declined 5% year over year in Q1 FY27 because of lower lenalidomide sales. (5 expanding across 2 engines)

The technology moat broadened through first-to-market and complex-product activity. In Q4 FY26, Dr. Reddy’s secured approval for generic semaglutide injection in Canada, launched semaglutide in India, and advanced its abatacept biosimilar application. By Q1 FY27, it had launched semaglutide injection in Canada as the first company and launched another complex generic, nintedanib, in North America. The latest state therefore shows a stronger complex-generic and biosimilar pipeline. (4 expanding, 1 contracting)

North America remained the largest disclosed geography but contracted materially. Revenue declined 13% year over year to ₹3,241 Cr and 5% sequentially, mainly because of product-specific price erosion and lower lenalidomide sales. This directly reflects the structural pressure in US generics and later became more severe in the baseline period. (5 contracting)

Peptide manufacturing capacity is being expanded across API production and finished-product filling. Current Semaglutide supply is supported by partners with capacity for 12 million pens, while two FTO-11 cartridge lines could theoretically support up to 50 million units after qualification. API investment has potential capacity of up to 800 kg and is intended to support Semaglutide, Liraglutide and more than 40 additional peptide programs. This is a new, expanding capacity platform, but much of the future capacity remains theoretical. (1 accelerating, 1 steady across 2 signals, 1 leading indicator)

The US product pipeline remains substantial, with 73 pending ANDAs, including 46 Para IV filings and 20 first-to-file filings as of September 2025. However, no prior-quarter count is provided in this document, so the pipeline's multi-quarter direction cannot be established. (5 new trend across 5 signals)

India growth strengthened modestly on a reported basis, rising from 17% YoY in the previously extracted period to 19% in Q3 FY26. Organic growth was above 17%, indicating that most of the increase was generated internally rather than through acquisitions. Management described 15%-16% growth as sustainable and said organic growth was approximately 17%-18%, making the latest trend positive but not a clear acceleration beyond one quarter. (3 accelerating, 2 decelerating across 5 signals, 2 leading indicators)

Emerging Markets growth is strong and accelerating sequentially: revenue growth increased from 14% YoY to 18% QoQ in Q2 FY26, while revenue rose from Rs. 1,455 Cr in Q2 FY25 to Rs. 1,655 Cr. Growth is supported by 50 product launches in H1 FY26 and 48 countries served. (4 accelerating, 1 decelerating across 5 signals, 2 leading indicators)

The main near-term growth constraints are semaglutide quality and supply issues, US lenalidomide sales decline, pricing pressure in several markets, higher solvent and freight costs, and regulatory observations at the Bachupally biologics facility. These risks could delay product launches or reduce profitability. — Product quality, pricing and regulatory headwinds: North America revenue down 35% YoY; Europe NRT revenue down 2% YoY

Semaglutide API problems have already caused out-of-specification batches, an inventory provision and related costs. This creates a risk of further product recalls, supply interruption, lost sales and additional write-offs. [REGULATORY] (+1 more risk)

The risk was visible in the older quarter and remained significant in Q2 FY26. North America revenue declined from ₹3,728 crore in Q2 FY25 to ₹3,241 crore in Q2 FY26, a fall of ₹487 crore or approximately 13%. Management attributed the decline partly to lower lenalidomide sales. The business also declined from ₹3,412 crore in Q1 FY26, showing continued sequential weakening. This confirms concentration in important products and vulnerability to product-specific revenue loss. (5 intensifying, 2 high-severity)

The January transcript provides an earlier, pre-disruption view of this risk. Semaglutide had received Indian approval, local manufacturing licences had been secured, and the company planned an India launch on March 21, 2026. However, Health Canada had issued a Notice of Non-Compliance requiring additional information, and the company was awaiting a response. Capacity was limited to about 12 million pens for the relevant period, with primary reliance on Stelis fill-and-finish. The July baseline shows that this risk later materialised significantly through rejected batches, unused material, a ₹240 crore provision and a planned restart, so the risk intensified materially after January. (1 intensifying, 1 high-severity)

This was already a high-severity regulatory risk in Q2 FY26. The Bachupally pre-approval inspection resulted in five Form 483 observations, and the FDA issued a Complete Response Letter for rituximab. Management said the issues were addressable but acknowledged that the first manufacturing line might need to be replaced by an alternate fill-and-finish line. Compared with the Jul 2026 baseline, the risk remained high and later reporting referred to seven observations, so the concern did not resolve and may have worsened in detail. (5 intensifying, 3 high-severity)

In Q2 FY26, the gross margin fell to 54.7%, down 492 basis points year-on-year, while EBITDA margin was 26.7%, down 174 basis points. Management explicitly said lenalidomide sales would be lower in Q3 and could largely disappear by Q4. Compared with the Jul 2026 baseline, profitability later deteriorated further, with reported EBITDA margin at 12.5% and 15.4% excluding the semaglutide provision. The risk therefore intensified materially. (5 intensifying, 4 high-severity)